Abstract
Background
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common mental disorders affecting children and adults. Previous systematic reviews have provided estimates of ADHD-associated costs but were limited to the USA and Europe.
Objectives
This study aimed to systematically summarise all global evidence on the economic burden of ADHD.
Methods
A systematic search for published studies on costs of ADHD was conducted in EconLit, EMBASE, PubMed, ERIC, and PsycINFO. Additional literature was identified by searching the reference lists of eligible studies. The quality of the studies was assessed using the Larg and Moss checklist.
Results
This review included 44 studies. All studies were conducted in high-income countries and were limited to North America and Europe except for four studies: two in Asia and two in Australia. Most studies were retrospective and undertook a prevalence-based study design. Analysis revealed a substantial economic impact associated with ADHD. Estimates based on total costs ranged from $US831.38 to 20,538 for per person estimates and from $US356 million to 20.27 billion for national estimates. Estimates based on marginal costs ranged from $US244.15 to 18,751.00 for per person estimates and from $US12.18 million to 141.33 billion for national estimates. Studies that calculated economic burden across multiple domains of direct, indirect, and education and justice system costs for both children and adults with ADHD reported higher costs and translated gross domestic product than did studies that captured only a single domain or age group.
Conclusions
Despite the wide variation in methodologies in studies reviewed, the literature suggests that ADHD imposes a substantial economic burden on society. There is a dire need for cost-of-illness research in low- and middle-income countries to better inform the treatment and management of ADHD in these countries. In addition, guidelines on the conduct and reporting of economic burden studies are needed as they may improve standardisation of cost-of-illness studies.
Similar content being viewed by others
References
Berger I. Diagnosis of attention deficit hyperactivity disorder: much ado about something. Isr Med Assoc J. 2011;13(9):571–4.
Gentile JP, Atiq R, Gillig PM. Adult ADHD: diagnosis, differential diagnosis, and medication management. Psychiatry (Edgmont). 2006;3(8):25–30.
Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Dtsch Arztebl Int. 2017;114(9):149–59.
Franke B, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28(10):1059–88.
D’Agati E, Curatolo A, Mazzone L. Comorbidity between ADHD and anxiety disorders across the lifespan. Int J Psychiatry Clin Pract. 2019;23(4):238–44.
Zulauf CA, et al. The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Curr Psychiatry Rep. 2014;16(3):436.
Le HH, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry. 2014;23(7):587–98.
Doshi JA, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51(10):990–1002.
Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–27.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–71.
Turner HC, et al. Adjusting for inflation and currency changes within health economic studies. Value Health. 2019;22(9):1026–32.
World Bank. GDP (current US$). 2018. https://data.worldbank.org/indicator/NY.GDP.MKTP.CD.
Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed Medscape Gener Med. 2006;8:3.
Birnbaum HG, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195–205.
Braun S, et al. Treatment Costs of Attention Deficit Hyperactivity Disorder in Germany. European Journal of Health Economics. 2013;14(6):939–45.
Burd L, et al. Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol. 2003;18(8):555–61.
Casadei G, et al. Italian regional health service costs for diagnosis and 1-year treatment of ADHD in children and adolescents. Int J Mental Health Syst. 2017;2017:11.
Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the Medical Expenditure Panel Survey. Arch Pediatr Adolesc Med. 2002;156(5):504–11.
Daley D, et al. The economic burden of adult attention deficit hyperactivity disorder: a sibling comparison cost analysis. Eur Psychiatry. 2019;61:41–8.
De Ridder A, De Graeve D. Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig. 2006;26(2):75–90.
de Jong NA, Williams CS, Thomas KC. Parent-Reported Health Consequences and Relationship to Expenditures in Children with ADHD. Maternal Child Health J. 2016;20(4):915–24.
Du Rietz E, et al. Trajectories of healthcare utilization and costs of psychiatric and somatic multimorbidity in adults with childhood ADHD: a prospective register-based study. J Child Psychol Psychiatry. 2020;61(9):959–68.
Fishman PA, Stang PE, Hogue SL. Impact of comorbid attention deficit disorder on the direct medical costs of treating adults with depression in managed care. J Clin Psychiatry. 2007;68(2):248–53.
Fletcher J, Wolfe B. Long-term consequences of childhood ADHD on criminal activities. J Ment Health Policy Econ. 2009;12(3):119–38.
Guevara J, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(1):71–8.
Gupte-Singh K, Singh RR, Lawson KA. Economic burden of attention-deficit/hyperactivity disorder among pediatric patients in the United States. Value Health. 2017;20(4):602–9.
Hakkaart-van Roijen L, et al. Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2007;16(5):316–26.
Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatric Serv. 2005;56(12):1593–9.
Hodgkins P, et al. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord. 2011;13:2.
Holden SE, et al. The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the united kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health. 2013;7:1.
Hong M, et al. Economic burden and disability-adjusted life years (DALYs) of attention deficit/hyperactivity disorder. J Attention Disord. 2019;2019:1087054719864632.
Jones DE, Foster EM. Service use patterns for adolescents with adhd and comorbid conduct disorder. J Behav Health Serv Res. 2009;36(4):436–49.
Kawatkar AA, et al. Impact of mental health comorbidities on health care utilization and expenditure in a large US managed care adult population with ADHD. Value Health. 2014;17(6):661–8.
Kessler RC, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med. 2005;47(6):565–72.
Kessler RC, et al. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2009;39(1):137–47.
Klora M, et al. Costs and treatment patterns of incident ADHD patients—a comparative analysis before and after the initial diagnosis. Health Econ Rev. 2015;5(1):1–9.
Klora M, et al. Age- and gender-specific costs as well as drug therapies of ADHD patients. Gesundheitswesen. 2016;78(7):e23–9.
Leibson CL, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. J Am Med Assoc. 2001;285(1):60–6.
Li H-J, et al. Outpatient rehabilitation resources and medical expenditure in children with attention-deficit hyperactivity disorder in Taiwan. PLoS ONE. 2018;13(6):e0199877.
Libutzki B, et al. Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. Eur Psychiatry. 2019;58:38–44.
Libutzki B, et al. Disease burden and direct medical costs of incident adult ADHD: a retrospective longitudinal analysis based on German statutory health insurance claims data. Eur Psychiatry. 2020;63(1):e86.
Mandell DS, et al. Economic grand rounds: medical expenditures among children with psychiatric disorders in a Medicaid population. Psychiatric Serv (Washington, DC). 2003;54(4):465–7.
Marks DJ, et al. Profiles of service utilization and the resultant economic impact in preschoolers with attention deficit/hyperactivity disorder. J Pediatr Psychol. 2009;34(6):681–9.
Pelham WE III, et al. The long-term financial outcome of children diagnosed with ADHD. J Consult Clin Psychol. 2020;88(2):160–71.
Quintero J, et al. Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry. 2018;18(1):40.
Ray GT, et al. Attention-deficit/hyperactivity disorder in children: Excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr Adolesc Med. 2006;160(10):1063–9.
Robb JA, et al. The estimated annual cost of ADHD to the US education system. School Mental Health. 2011;3(3):169–77.
Sciberras E, et al. Health care costs associated with parent-reported ADHD: a longitudinal australian population-based study. J Attention Disord. 2017;21(13):1063–72.
Sciberras E, et al. Social and economic costs of attention-deficit/hyperactivity disorder across the lifespan. J Attention Disord. 2020;2020:1087054720961828.
Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. PharmacoEconomics. 2005;23(1):93–102.
Swensen A, et al. Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. J Adolesc Health. 2004;35(4):346.e1-346.e9.
Swensen AR, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1415–23.
Telford C, et al. Estimating the costs of ongoing care for adolescents with attention-deficit hyperactivity disorder. Soc Psychiatry Psychiatr Epidemiol. 2013;48(2):337–44.
van der Kolk A et al. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. SpringerPlus 2015;4:224.
Young S, et al. The economic consequences of attention-deficit hyperactivity disorder in the Scottish prison system. BMC Psychiatry. 2018;18(1):210.
Zhao X, et al. Family Burden of raising a child with ADHD. J Abnorm Child Psychol. 2019;47(8):1327–38.
Ginsberg Y, et al. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature. Prim Care Companion CNS Disord. 2014;16:3.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No sources of funding were used to conduct this study or prepare this manuscript.
Conflict of Interest
Anindit Chhibber, Alexandre Hikiji Watanabe, Chayutthaphong Chaisai, Sajesh K Veettil, and Nathorn Chaiyakunapruk have no conflicts of interest that are directly relevant to the content of this article.
Availability of data and material
Data sharing is not applicable as no new data were generated during the study. The data analysis file is available from the corresponding author upon request.
Ethics Approval
Not applicable.
Consent
Not applicable.
Author Contributions
NC conceived the idea of the research study. NC and AC designed the study plan. AC, AW, CC, and SV conducted the screening and data extraction for the studies. AC conducted the data analysis under supervision of NC. AC, AW, and NC wrote and contributed to the final manuscript.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chhibber, A., Watanabe, A.H., Chaisai, C. et al. Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. PharmacoEconomics 39, 399–420 (2021). https://doi.org/10.1007/s40273-020-00998-0
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-020-00998-0